[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Telehealth in Europe – From Pilot to Mainstream?

November 2010 | 43 pages | ID: T6643ECC81CEN
Ovum

US$ 2,995.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
License Price: US$ 7,490.00

Introduction

As healthcare providers struggle with acute budget restraints, there is a strong case for the deployment of telemonitoring to remedy the situation. This has helped with the identification of changes in patients’ well-being at an earlier stage, and has subsequently lead to a decrease in the number of emergency room visits and the average length of hospitalization.

Features and benefits
  • A mix of external and internal factors leads to an explosion of costs for the provision of healthcare.
Highlights

The major stakeholders for the provision of telehealth: payers (regional/national authorities, private health insurers), medical staff (doctors and nurses), and patients and governments have not until now been sufficiently aware of telehealth.As the pressures on healthcare payers to close the gaping hole between decreasing contributions and rising healthcare expenditures, it is important to explore more efficient ways of healthcare delivery. Available evidence based on pilots into the deployment of telehealth suggests that it has the potential to cut costs.

Your key questions answered
  • Understand how demographic as well as economic factors change the funding basis for healthcare provision.
  • Gain insight into the drivers and barriers for telemonitoring
  • Examples of telemonitoring pilots across Europe.

SUMMARY

Catalyst
Ovum view
Key messages
Limited evidence of effectiveness
Winning over stakeholders is key to adoption
More for less

MARKET CONTEXT: BUSINESS ISSUES IMPACT THE UPTAKE OF TELEHEALTH

The legal framework of telemonitoring in Europe
Telemonitoring drivers and barriers
No place like home: drivers of telemonitoring
Improved patient outcomes
Improved quality of life
Reduction of hospital admissions
Speedier hospital discharge
Help in screening ailments and faster channeling to the appropriate physician
Wider access to medical care
More cost-efficient provision of healthcare
Home alone: barriers to the adoption of telemonitoring
Lack of a sustainable reimbursement model
Stakeholder apprehension
Controversial effectiveness
Insufficient regulatory framework
Concerns about patient data
Limited interoperability
How reliable are the measurements?
Infrastructure requirements
Data protection – how safe is your data?
From pilot to mainstream?
Telehealth is not just for the chronically sick
Future areas of adoption

BUSINESS FOCUS: THE USE OF TELEMONITORING IN EUROPE

Predominant use of telemonitoring
Telemonitoring pilots and implementations in Europe
Selected applications and their insights
Medgate AG in Switzerland and its lessons
Study in neurosurgery at the University of Nuremberg-Erlangen, Germany
Whole Systems Demonstrator Programme (WSD) in the UK
Combined insights from various trials across Europe
Few telemonitoring studies provide clear-cut evidence of efficiency gains
Higher quality of life may be a significant benefit from telemonitoring

TECHNOLOGY FOCUS: TECHNOLOGY EVOLUTION AND THE COMPETITIVE LANDSCAPE

A basic understanding of telemonitoring
What manufacturers of telemonitoring solutions should consider
Accuracy
Compliance
Smooth integration with other devices
Need to adapt to users’ needs
What it will take to be successful in tomorrow’s telemonitoring market
Deeper integration of telehealth
Seamless service offering
Bridging the schism between healthcare buyers and users
Close cooperation with end users
Vendors benefit from lobbying
A more pronounced differentiation of devices is called for
Tomorrow’s telemonitoring will be integrated, consumer-driven, and mobile
Players in the telemonitoring space
Increasing industry commitment

RECOMMENDATIONS

Recommendations for payers
Create robust evidence
Redesign healthcare delivery models
Educate users
Campaign for your case
Recommendations for vendors
Continue to invest in clinical research
Win over stakeholders
Security
Alternative views

APPENDIX

Further reading
Methodology
Definitions
Author
Ovum Consulting
Disclaimer


More Publications